Low molecular weight cationic lipids for oligonucleotide delivery

Patent metadata

Field	Value
Publication number	US-9458090-B2
Application number	US-201514682494-A
Country	US
Kind code	B2
Filing date	Apr 9, 2015
Priority date	Oct 21, 2010
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

First claim

What is claimed is:

1. A lipid nanoparticle comprising an oligonucleotide and a lipid of Formula A:

wherein:
R 1 and R 2 are independently selected from H, (C 1 -C 6 )alkyl, heterocyclyl, and polyamine, wherein said alkyl, heterocyclyl and polyamine are optionally substituted with one to three substituents selected from R′, or R 1 and R 2 can be taken together with the nitrogen to which they are attached to form a monocyclic heterocycle with 4-7 members optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic heterocycle is optionally substituted with one to three substituents selected from R′;
R 3 is selected from H and (C 1 -C 6 )alkyl, said alkyl optionally substituted with one to three substituents selected from R′;
R′ is independently selected from halogen, R″, OR″, SR″, CN, CO 2 R″ or CON(R″) 2 ;
R″ is independently selected from H and (C 1 -C 6 )alkyl, alkyl is optionally substituted with halogen and OH;
n is 0, 1, 2, 3, 4 or 5;
X is selected from O, NR″, (C═O)O, NR″(C═O), O(C═O)O, NR″(C═O)NR″, O(C═O)NR″, and NR″(C═O)O;
L 1 is selected from C 4 -C 24 alkyl and C 4 -C 24 alkenyl, said alkyl and alkenyl are optionally substituted with one or more substituents selected from R′; and
L 2 is selected from unsubstituted C 9 alkyl and unsubstituted C 9 alkenyl;
or any pharmaceutically acceptable salt or stereoisomer thereof.

2. The lipid nanoparticle of claim 1 , wherein in the lipid of Formula A
R 1 and R 2 are each methyl;
R 3 is H;
n is 3;
X is (C═O)O;
L 1 is selected from C 4 -C 24 alkyl and C 4 -C 24 alkenyl; and
L 2 is selected from C 3 -C 9 alkyl and C 3 -C 9 alkenyl;
or any pharmaceutically acceptable salt or stereoisomer thereof.

3. The lipid nanoparticle of claim 1 , wherein the lipid is:
(20Z,23Z)-nonacosa-20,23-dien-10-yl 4-(dimethylamino)butanoate (Compound 1); and
(18Z)-heptacos-18-en-10-yl4-(dimethylamino)butanoate (Compound 2);
or any pharmaceutically acceptable salt or stereoisomer thereof.

4. The lipid nanoparticle according to claim 1 , wherein the oligonucleotide is siRNA or miRNA.

5. The lipid nanoparticle according to claim 1 , wherein the oligonucleotide is siRNA.

6. The lipid nanoparticle of claim 1 , wherein L 1 is C 4 -C 24 alkenyl.

7. The lipid nanoparticle of claim 6 , wherein L 1 is C 12 -C 24 alkenyl.

8. The lipid nanoparticle of claim 7 , wherein L 1 is C 19 alkenyl.

9. The lipid nanoparticle of claim 7 , wherein L 1 is

10. The lipid nanoparticle of claim 1 , wherein R 1 and R 2 are independently selected from H, methyl, ethyl and propyl.

11. The lipid nanoparticle of claim 10 , wherein R 1 and R 2 each are methyl.

12. The lipid nanoparticle of claim 1 , wherein R 3 is H or methyl.

13. The lipid nanoparticle of claim 12 , wherein R 3 is H.

14. The lipid nanoparticle of claim 1 , wherein n is 2, 3 or 4.

15. The lipid nanoparticle of claim 14 , wherein n is 3.

16. The lipid nanoparticle of claim 1 , wherein X is O, NR″, (C═O)O, NR″(C═O), O(C═O)O, NR″(C═O)NR″, O(C═O)NR″ or NR″C(C═O)O.

17. The lipid nanoparticle of claim 16 , wherein X is (C═O)O.

Assignees

• Sirna Therapeutics Inc

Inventors

• Colletti Steven L
• Stanton Matthew G

Classifications

• C07C229/12 Primary

  to carbon atoms of acyclic carbon skeletons · CPC title

• C12N15/88

  using microencapsulation, e.g. using {amphiphile} liposome vesicle · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• A61K31/221

  with compounds having an amino group, e.g. acetylcholine, acetylcarnitine · CPC title

• A61K9/5123

  Organic compounds, e.g. fats, sugars · CPC title